See the DrugPatentWatch profile for cosentyx

Based on the information available, there is no definitive guidance suggesting that Cosentyx (secukinumab) should be delayed after receiving a COVID-19 vaccine. The Centers for Disease Control and Prevention (CDC) recommends that individuals get vaccinated against COVID-19 as soon as they are eligible, regardless of whether they are currently taking any medications, including biologic therapies like Cosentyx [1].

Cosentyx is a prescription medication used to treat several conditions, such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis [2]. It is a biologic therapy that works by targeting a specific protein in the body (interleukin-17A) to reduce inflammation [2].

According to DrugPatentWatch.com, Cosentyx is manufactured by Novartis and is currently not facing any patent expirations or challenges in major markets [3].

It is always essential to consult with a healthcare provider for personalized medical advice, especially when considering any changes to medication schedules or vaccinations. Healthcare providers can provide guidance based on an individual's specific medical history and current health status.

In summary, there is no evidence or recommendation to delay Cosentyx administration after receiving a COVID-19 vaccine. However, it is crucial to consult with a healthcare provider for personalized advice.

Sources:

[1] Centers for Disease Control and Prevention. (2021). COVID-19 Vaccines for Moderately to Severely Immunocompromised People. <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/immuno.html>
[2] Cosentyx (secukinumab) [prescribing information]. (2021). East Hanover, NJ: Novartis Pharmaceuticals Corporation. <https://www.novartis.us/sites/www.novartis.us/files/cosentyx.pdf>
[3] DrugPatentWatch.com. (2022). Cosentyx (secukinumab) Drug Patent Information. <https://www.drugpatentwatch.com/drugs/cosentyx>